Adjuvant Treatment of Recent Onset Rheumatoid Arthritis by Selenium Supplementation: Preliminary Observations

Peretz, Anne; Nève, Jean; Duchateau, Jean; Famaey, Jean Pierre

doi:10.1093/rheumatology/31.4.281

Cited by 55 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effectiveness of Se in many other autoimmune diseases like rheumatoid arthritis (Peretz et al 1992), asthma (Hasselmark et al 1993, Kadrabova et al 1996, and lupus erythematosus (Juhlin et al 1982, Brown 2000 is well documented. It seems that the immunomodulatory effects of this element may be more prominent than the other effects.…”

Section: Discussionmentioning

confidence: 99%

Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses

Türker¹,

Kumanlıoğlu²,

Karapolat³

et al. 2006

Journal of Endocrinology

133

View full text Add to dashboard Cite

The aim of this study is to investigate the long-term (9 months) effects of variable doses (200/100 mg/day) of L-selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean ageZ40$1G13$3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving L-thyroxine to keep serum TSH%2 mIU/l. Group S2 (nZ48, mean TPOAbZ803$9G483$8 IU/ml) received 200 mg L-selenomethionine per day, orally for 3 months, and group C (nZ40, mean TPOAbZ770$3G 406$2 IU/ml) received placebo. (2) 40 volunteers of group S2 were randomized into two age-and TPOAb-matched groups. Group S22 (nZ20) went on taking L-selenomethionine 200 mg/day, while others (group S21) lowered the dose to 100 mg/day. (3) 12 patients of group S22 (group S222) went on taking L-selenomethionine 200 mg/day, while 12 patients of group S21 (S212) increased the dose to 200 mg/day. Serum titers of TPOAb decreased significantly in group S2 (26$2%, P!0$001), group S22 (23$7%, P!0$01) and group S212 (30$3%, P!0$01). There were no significant changes in group C and group S222 (PO0$05). TPOAb titers increased significantly in group S21 (38$1%, P!0$01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5$2%, P!0$01). L-selenomethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 mg/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time.

show abstract

Section: Discussionmentioning

confidence: 99%

Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses

Türker¹,

Kumanlıoğlu²,

Karapolat³

et al. 2006

Journal of Endocrinology

133

View full text Add to dashboard Cite

show abstract

“…55 In a double-blind randomised controlled trial in a small group of RA patients, supplementation with 200 mcg Se as Se-yeast for 3 months, gave a significant reduction in pain and joint involvement. 56 There is evidence for a protective effect of Se in pancreatitis, a condition associated with a high level of oxidative stress. At Manchester Royal Infirmary, administration of Se (600 mcg/day) along with other antioxidants to patients with chronic and recurrent pancreatitis, significantly reduced pain and frequency of attacks.…”

Section: Thyroid Functionmentioning

confidence: 99%

The importance of selenium to human health

2000

View full text Add to dashboard Cite

“…In the first, a dose of 200 µg/d showed significant beneficial changes in the selenium group for pain at three months and number of joints involved at three and six months [80]. The second study used the same dose but both Se and placebo groups also received fish oil fatty acids at 30 mg/kg body weight [81].…”

Section: Intervention Studies With Seleniummentioning

confidence: 99%